NCT07174336 2026-04-17
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
12 trialsNCT07062965 2026-04-16
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Phase 3 Recruiting
NCT06380751 2026-04-14
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT04650581 2026-04-13
FINER
Canadian Cancer Trials Group
Phase 3 Active not recruiting
NCT05038735 2026-04-08
EPIK-B5
Novartis
Phase 3 Active not recruiting
NCT06764186 2026-04-08
CAPItana
AstraZeneca
Phase 3 Active not recruiting
NCT05696626 2026-04-07
ELAINEIII
LeonaBio
Phase 3 Recruiting
NCT06065748 2026-04-06
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT04851613 2026-04-02
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Laekna Limited
Phase 3 Active not recruiting
NCT06982521 2026-04-02
ReDiscover-2
Relay Therapeutics, Inc.
Phase 3 Recruiting
NCT06954961 2026-03-31
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
InventisBio Co., Ltd
Phase 3 Recruiting
NCT06635447 2026-03-27
CAPItrue
AstraZeneca
Phase 3 Active not recruiting